Narrative Summary

Research

Dr. Lodder has conducted academic research at the University of Kentucky using grants totaling over $18 million. This research led to 30 patents and pending patent applications, the founding of five new companies, and his becoming president of a NASDAQ company.The first start-up company, InfraReDx, was founded in 1998 and raised over $210 million in private capital for novel research before being sold to a $5 billion company in Japan. InfraReDx still operates from Burlington, Massachusetts. In April 2008, InfraReDx received FDA marketing clearance for the Lipiscan coronary imaging system originally invented and patented by Dr. Lodder. His second company, Prescient, raised $49 million for research and development, and Spherix invested $47 million in drug development before it was sold in separate transactions. The total of over $300 million in capital investment helps meet the mandate to commercialize university research.

Dr. Lodder served as president and was on the board of directors of Spherix (NASDAQ:SPEX). Dr. Lodder has conducted multiple clinical trials for his companies, NIH and DARPA, including global phase 2 and phase 3 clinical trials of an oral diabetes medication in 60 hospitals and clinics worldwide. Spherix licensed its lead drug candidate for dyslipidemia, SPX106T, from Dr. Lodder’s lab at the University of Kentucky. Escent Technologies commercialized a solid-state spectral imager invented by Dr. Lodder for a NASA robotic mission to Mars.

Dr. Lodder is author of 120 publications and over 300 presentations. Dr. Lodder served as president and then CEO of Spherix (NASDAQ: SPEX) before Biospherics. He joined TVM Venture Partners and assisted portfolio companies in commercialization.

The Google citation index lists over 4700 citations to Dr. Lodder's research (an average of 42 citations/publication). Dr. Lodder is the recipient of two national and five international research achievement awards. Dr. Lodder's doctoral graduates have entered academia, government, and industry.

Teaching

Dr. Lodder's teaching is demonstrated not only by teaching evaluations, but also in external evaluations of his course web products submitted by scientists worldwide (for PHR 510, CHE 626 and CHE 522), by the public at large (who use the guide to Home Diagnostic Kits created by PHR 895 about 15,000 times each day), and by peer-reviewed publication of the term papers written as lab reports for his courses.

Service

Dr. Lodder has served on several NIH study sections and has been invited to NSF, NIH and DARPA workshops. He was appointed by the Food and Drug Administration to serve on their Process Analytical Technologies (PAT) subcommittee, which aims to revolutionize the pharmaceutical industry by replacing the GMP standards under which drugs have been released for the past 40 years with new, science-based PAT methods. He has recently begun working with the U.S. Pharmacopoeia in this capacity as well. Dr. Lodder has served as both chair and vice chair of the local section of the American Chemical Society, and Treasurer of the local AAUP. Dr. Lodder has been twice elected to the Pharmaceutical Sciences Executive Committee by the division faculty. While in the College of Pharmacy, he also serves the university through affiliations with the Chemistry Department, Department of Electrical and Computer Engineering, Center for Computational Sciences, Graduate Center for Nutritional Sciences, and Gill Heart Institute